Investors and Media
  Events, Presentations and Webcasts
Press Releases
  Bionovo in the News
  Stock Details
  Analyst Coverage
  SEC Filings
  SEC Filings - XBRL Content
  Corporate Governance


$N/A (N/A)


Press Release


Printer Friendly Version View printer-friendly version

Bionovo to Host a Conference Call to Discuss Menerba's Tolerability Trial Results

EMERYVILLE, Calif., Aug. 29, 2011 /PRNewswire/ -- Bionovo, Inc. (NASDAQ: BNVI) announced today that it will host a conference call on Tuesday, August 30, 2011, to discuss the results of the completed Tolerability Trial of its drug candidate for menopausal hot flashes, Menerba™ (or MF101), at 2:00 p.m. Pacific Time. The company will also discuss Menerba's overall clinical development plan and the impending Phase 3 study scheduled to start shortly.

Interested parties can access the call by dialing 800-926-5187, or can listen via a live audio only webcast, which can be found at A replay of the call will be available by dialing 800-633-8284 (replay code: 21536583) through September 2, 2011 and archived via audio webcast at

About Bionovo, Inc.

Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources, which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes it has discovered new classes of drug candidates within its rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and its stock is traded on the NASDAQ Capital Market under the symbol "BNVI." For more information about Bionovo and its programs, visit

SOURCE Bionovo, Inc.